Tuesday, March 2, 2021
NIH invests in next iteration of public-private partnership to advance precision medicine research for Alzheimerâs disease
The National Institutes of Health has launched the next version of the Accelerating Medicines Partnership (AMP) Alzheimerâs disease program (AMP AD 2.0) to expand the open science, big data approach for identifying biological targets for therapeutic intervention. AMP AD 2.0 is supporting new technologies, including cutting-edge, single-cell profiling and computational modeling, to enable a precision medicine approach to therapy development. Managed through the Foundation for the NIH (FNIH), AMP AD 2.0 brings together NIH, industry, non-profit and other organizations with a shared goal of using open science practices to accelerate the discovery of new drug targets, biomarkers and disease subtypes.
Liver Cancer Treatment Market to Witness Robust Expansion by 2027 with Top Key players like Bristol‑Myers Squibb Company, Eisai Inc , Exelixis Inc, Merck & Co Inc , Bayer AG – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
Combo Shows Impressive Survival Results in First-Line RCC
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.